Marex Group’s China SXT Pharmaceuticals SXTC Stock Holding History

Marex Group’s Portfolio SXTC Stock Details SXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-34	Closed	-$164K	–	659
2023 Q4	$164K	Buy	+34	New	+$94.6K	0.01%	466

Other funds holding SXTC

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marex Group's SXTC Position: Q1 2024 in Review

Marex Group sold out of China SXT Pharmaceuticals (SXTC) in Q1 2024, closing a stake of 34 shares — an estimated $164K sold.

Marex Group first reported a position in SXTC in Q4 2023 and held it in 1 quarter. The position peaked at $164K in Q4 2023. 1 fund tracked by Wall St. Rank holds SXTC as of Q1 2024.

Marex Group reported no remaining China SXT Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Marex Group sold 34 China SXT Pharmaceuticals shares in Q1 2024, an estimated $164K.
Marex Group first reported a position in China SXT Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Marex Group's China SXT Pharmaceuticals position peaked at $164K in Q4 2023.
1 fund tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2024.

Based on Marex Group's 13F filing for Q1 2024, filed 2 Apr 2026.